Patents Examined by Samantha L Shterengarts
  • Patent number: 11607416
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Patent number: 11608309
    Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 21, 2023
    Inventors: Francis Johnson, Lorne Golub
  • Patent number: 11603349
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: March 14, 2023
    Assignee: Certa Therapeutics Pty Ltd
    Inventors: Thomas Miller, Nikolaos Papaioannou
  • Patent number: 11603372
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: March 14, 2023
    Assignee: VioGen Biosciences, LLC
    Inventor: Ashok Bajji
  • Patent number: 11597703
    Abstract: Provided herein are compounds of formula I, compositions comprising the compounds and method of treating various diseases with the compounds and compositions.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: March 7, 2023
    Assignee: Histogen, Inc.
    Inventors: Alfred P. Spada, Robert J. Temansky, Michael Mueller
  • Patent number: 11590116
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: February 28, 2023
    Inventors: Christina Owens, Svitlana Kulyk, Steven D. E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
  • Patent number: 11584728
    Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: February 21, 2023
    Inventors: Dennis Keefe, Guozhu Zheng, Pavels Arsenjans
  • Patent number: 11584722
    Abstract: Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 21, 2023
    Assignee: Xiamen Vivohealths Technology Co., Ltd.
    Inventors: Xianming Deng, Shengcai Lin, Chensong Zhang
  • Patent number: 11584708
    Abstract: The invention relates to a method for the preparation of a 4,5-dihydroxyisoleucine derivative comprising the steps of asymmetric Claisen rearrangement of a Z-aminocrotyl-glycin ester and subsequent kinetic resolution of the product diastereomer mix by acylase, and subsequent Sharpless dihydroxylation of the resulting 2-amino-3-methylpent-4-enoic acid derivative.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: February 21, 2023
    Assignee: Heidelberg Pharma Research GmbH
    Inventors: Caroline Knittel, Mary-Ann Siegert, Roderich Süssmuth, Christoph Wink, Gerhard Jas
  • Patent number: 11584723
    Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: February 21, 2023
    Assignee: CV6 Therapeutics (NI) Limited
    Inventors: Mark Spyvee, Pravin S. Shirude
  • Patent number: 11584736
    Abstract: Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X?, Y?, Z?, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 21, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Jinha Yu, Antonella Ciancetta, Zhiwei Wen, Young-Hwan Jung
  • Patent number: 11584761
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 21, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Patent number: 11584752
    Abstract: A general and modular mechanophore platform that efficiently releases a cargo molecule via a mechanically triggered cascade reaction is described, along with methods of synthesis and use thereof. The mechanophore platform comprises a stable Diels-Alder adduct mechanophore comprising a 2-furylcarbinol derivative as its diene component, wherein the 2-furylcarbinol derivative is, in turn, pre-loaded with a covalently attached cargo molecule, and wherein the Diels-Alder adduct mechanophore is embedded into a polymer chain or polymer network, such that the mechanophore platform undergoes the retro [4+2] cycloaddition reaction under mechanical force to reveal the unstable 2-furylcarbinol derivative, which, in turn, easily decomposes under mild conditions to release its molecule cargo.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: February 21, 2023
    Assignee: California Institute of Technology
    Inventors: Maxwell J. Robb, Xiaoran Hu, Tian Zeng
  • Patent number: 11578059
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 14, 2023
    Assignee: Imago Biosciences. Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
  • Patent number: 11578082
    Abstract: A compound is represented by Chemical Formula 1. The compound may be included in, a film, an infrared sensor, a combination sensor, and/or an electronic device. In Chemical Formula 1, X, Y1, Y2, Z1, Z2, Q, R1, and R2 are the same as described in the detailed description.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: February 14, 2023
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Ohkyu Kwon, Rae Sung Kim, Dong-Seok Leem, Changki Kim, Insun Park
  • Patent number: 11572344
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula where R1, R2, R2a, R3, R3a, and X are as described herein.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 7, 2023
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 11572357
    Abstract: The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: February 7, 2023
    Assignee: Bayer Animal Health GmbH
    Inventors: Walter Hübsch, Nils Griebenow, Hans-Georg Schwarz, Daniel Kulke, Claudia Böhm, Kirsten Börngen, Bernd Alig, Wei Zhuang, Iring Heisler, Thomas Ilg, Johannes Köbberling, Adeline Köhler, Niels Lindner, Ulrich Görgens, Claudia Welz, Maike Hink
  • Patent number: 11564926
    Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: January 31, 2023
    Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.
    Inventors: D. Keith Hester, II, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Lianhe Shu, Ping Wang, Duk Soon Choi
  • Patent number: 11560387
    Abstract: In a preferred embodiment, there is provided a protecting group for protecting the thiol side chain of a cysteine residue, the protecting group comprising a Diels-Alder cycloadduct of a furan and a maleimide, and optionally, a linker interposed between the thiol side chain and the Diels-Alder cycloadduct.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: January 24, 2023
    Inventors: John Frederick Trant, Daniel Meister, Sarah Nasri, Anthony Emanuel Chifor, John James Hayward, Seyedeh Maryamdokht Taimoory, Mohadeseh Dashti-Pour
  • Patent number: 11554172
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: January 17, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish